¿Qué pasa después del sexo?
Entre Animaciones Ep. 4: Inside Out
Una pitón en tu jardín | Noticias Paralelas
mi istoria
Charrando y Rajando 1x02 - Arte y flipadas de blancos
Ep. 13 - ¡Qué asco!
EP 12. Emociones. Como Gestionarlas
Richard Schilsky, M.D. - A Deep Passion for Cancer Medicine
Dr. Larry Einhorn: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. Larry Einhorn: What is Your Opinion of Patients and Caregivers Searching the Internet for Information?
Dr. Larry Einhorn: What are the Biggest Challenges We Face in Delivering Effective Cancer Care in the Next Decade?
Dr. Larry Einhorn on "What Have Been the Most Significant Changes in Cancer Care over the Past Decade or Two?"
Are molecular markers just for NSCLC?
Dr. Larry Einhorn: Are You Optimistic That a Supercomputer Such as Watson Will Be Able To Improve Cancer Care?
ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (audio)
ASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (audio)
ASCO Lung Cancer Highlights, Part 8: The Biomarkers France Study (audio)
ASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC (video)
ASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC (audio)
ASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (video)
ASCO Lung Cancer Highlights, Part 8: The Biomarkers France Study (video)
ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (video)
ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (audio)
No Clear Answer for Non-Clear Cell Kidney Cancer
What Is Non-Clear Cell Kidney Cancer?
Cabozantinib for Late Stage Kidney Cancer
Data from Keynote 12 Nivolumab and Pembrolizumab
Keynote 55 Pembrolizumab for Heavily Pre-Treated Patients
Immuno-oncology Developments - Combinations and Use as First-Line Therapy
Using Biomarkers in Immunotherapy
Rova-T Shows Promise in Small Cell Lung Cancer
Are There Less Toxic Alternatives to the Extreme Regimen
Using Immunotherapy as First-Line Treatment and in Combinations
The Immune System and PD-1 Inhibitors
Does Current Evidence Support Favoring Proton-Beam Radiation
Common Side Effects of PD-1 Inhibitors
ASCO 2016 LC RT Vid 8 - Promising Early Results for Treatments
Adjuvant Chemotherapy for Elderly and Frail Patients
How Promising Are The Results From Checkmate 141?
ASCO 2020: New Developments in the Treatment of Hard to Treat Cancers
Los Normanolos Radio Espacio Personal
An ASCO 2014 Recap with Edward McClay MD
EP.1: Pizza para dos
Apuntes de Psicología #16 La emoción de asco
ASCO 2019: Form Biomarker Discovery to Photo-Immunotherapy
Beyond the Emergence of Targeted Therapies and the Treatment of Bladder Cancer
31_ASOC, a scuola di open coesione
Improving Treatment for Patients with Pancreatic Cancer
Advancing Treatment for Patients with Advanced Triple Negative Breast Cancer
Results from ASCO 2018: Expanding the Reach of Precision Medicine (Part 1)
Discover more
Search
